| Literature DB >> 23573182 |
Sandra Wathlet1, Tom Adriaenssens, Ingrid Segers, Greta Verheyen, Lisbet Van Landuyt, Wim Coucke, Paul Devroey, Johan Smitz.
Abstract
Cumulus cell (CC) gene expression is being explored as an additional method to morphological scoring to choose the embryo with the highest chance to pregnancy. In 47 ICSI patients with single embryo transfer (SET), from which individual CC samples had been stored, 12 genes using QPCR were retrospectively analyzed. The CC samples were at the same occasion also used to validate a previously obtained pregnancy prediction model comprising three genes (ephrin-B2 (EFNB2), calcium/calmodulin-dependent protein kinase ID, stanniocalcin 1). Latter validation yielded a correct pregnant/non-pregnant classification in 72% of the samples. Subsequently, 9 new genes were analyzed on the same samples and new prediction models were built. Out of the 12 genes analyzed a combination of the best predictive genes was obtained by stepwise multiple regression. One model retained EFNB2 in combination with glutathione S-transferase alpha 3 and 4, progesterone receptor and glutathione peroxidase 3, resulting in 93% correct predictions when 3 patient and treatment cycle characteristics were included into the model. This large patient group allowed to do an intra-patient analysis for 7 patients, an analysis mimicking the methodology that would ultimately be used in clinical routine. CC related to a SET that did not give pregnancy and CC related to their subsequent frozen/thawed embryos which ended in pregnancy were analyzed. The models obtained in the between-patient analysis were used to rank the oocytes within-patients for their chance to pregnancy and resulted in 86% of correct predictions. In conclusion, prediction models built on selected quantified transcripts in CC might help in the decision making process which is currently only based on subjective embryo morphology scoring. The validity of our current models for routine application still need prospective assessment in a larger and more diverse patient population allowing intra-patient analysis.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23573182 PMCID: PMC3616108 DOI: 10.1371/journal.pone.0054226
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Genes analyzed in cumulus cells for pregnancy prediction.
| Gene symbol (name) | General Function | Previously described as oocyte quality marker in human CC | References |
|
| B-Class Ephrins are transmembrane proteins possibly involved in luteinization events | Higher in the CC of pregnant ICSI patients |
|
|
| Member of the Ca2+/calmodulin-dependent protein kinase 1 subfamily of serine/threonine kinases | Higher in the CC of pregnant ICSI patients |
|
|
| Decreases FSH induced progesterone production in rat granulosa cell cultures | Tended to be lower in pregnant ICSI patients |
|
|
| Cellular antioxidant defense enzyme | Not yet described |
|
|
| Helps in the detoxification of hydrogen peroxide | Negative predictor for early cleavage embryos |
|
|
| Detoxification function next to a function in progesterone production | Not yet described |
|
|
| Detoxification function | Not yet described |
|
|
| Can play a role in cell proliferation and differentiation. It was shown to be related to follicle development in adult mice. | Not yet described |
|
|
| Anti-apoptotic effect through the binding of progesterone in cultured human granulosa cells | Lower expressed in good morphology blastocysts. Up- regulated in follicular cells of pregnant patients (array results) |
|
|
| Receptor for inositol 1,4,5-triphsopahte, releasing calcium from the endoplasmatic reticulum | Up-regulated in non-early cleavage embryos (array results) |
|
|
| Glucose transporter responsible for the facilitated transport of glucose through the plasma membrane of mammalian cells | Not yet described |
|
|
| Can mediate cell-cell and cell-matrix interactions. Can activate TGFB1 | Not yet described |
|
(A) Refers to information from the ‘General Function’ column; (B) Refers to the information from the ‘Previously described as oocyte quality marker in human CC’ column; CC: cumulus cells; FSH: Follicle stimulating hormone; ICSI: intra-cytoplasmic sperm injection.
Figure 1Overview of the samples used in this study.
This figure represents the distribution of the samples used for the different analyses performed in this study. The grey background fields delimit the samples that were used for the specific analyses which are marked on the left side of the field. SET: single embryo transfer; FRET: frozen embryo transfer cycle; rFSH: recombinant Follicle Stimulating Hormone.a:[15].
Strategy over 3 studies to obtain the strongest quality related genes on stored cumulus cells from ICSI patients.
| Wathlet et al. 2011 | Wathlet et al. 2012 | Current study | |
| Genes tested with QPCR |
|
|
|
| Stimulation protocol | antagonist rFSH (25 patients) agonist HP-hMG (20 patients) | Antagonist rFSH (33 patients) | Antagonist rFSH (47 patients) |
| Embryo culture medium | BlastAssist System (Medicult) | Vitrolife G7 (Vitrolife) | SAGE (CooperSurgical) |
| End points | Embryo morphology (75 CC for rFSH and 67 CC for HP-hMG from 2×10 patients). Clinical pregnancy (42 patients of both stimulation protocols of which 19 pregnant = 19 COC) | Embryo morphology (99 CC). Biochemical and live birth pregnancy (16 pregnant, 17 non-pregnant = 33 COC) | Live birth pregnancy inter-patient analysis (19 live birth, 28 non-pregnant = 47 COC). Pregnancy intra-patient (7 patients with 2 or 3 CC from the same retrieval cycle) |
| Best genes retained for next study | Pregnancy prediction: | Pregnancy prediction: | To be determined in the current study |
The gene expression of cumulus cells (CC) related to different embryo morphology or pregnancy outcome of the corresponding oocytes in ICSI was assessed for three gene panels on three different sample sets. The genes found most predictive in each sample set were tested in the subsequent independent patient samples set. Genes marked in bold were retained as best predictive genes from the previous study. MII: metaphase II oocytes; COC: cumulus oophorus complex; rFSH: recombinant Follicle Stimulating Hormone; HP-hMG: Highly Purified human Menopausal Gonadotropin.
Patient and cycle characteristics.
| Pregnant | Non-pregnant | |||||||
| Variable | Unit | average | SD | n | average | SD | n | t-test |
|
| Year | 30 | 4 | 19 | 31 | 5 | 28 | ns |
|
| kg/m2 | 23 | 4 | 17 | 23 | 4 | 25 | ns |
|
| # | 9 | 2 | 19 | 8 | 1 | 28 | ns |
|
| U/day | 167 | 34 | 19 | 169 | 36 | 28 | ns |
|
| U/l | 11 | 3 | 16 | 12 | 4 | 26 | ns |
|
| U/l | 1.88 | 1.46 | 10 | 1.18 | 0.86 | 24 | ns |
|
| ng/l | 150 | 98 | 16 | 162 | 87 | 26 | ns |
|
| µg/l | 0.79 | 0.26 | 16 | 0.77 | 0.42 | 26 | ns |
|
| # | 10 | 5 | 19 | 9 | 5 | 28 | ns |
|
| # | 6 | 3 | 19 | 6 | 3 | 28 | ns |
|
| % | 89 | 10 | 19 | 80 | 15 | 28 | ns |
|
| % | 82 | 15 | 19 | 87 | 16 | 28 | ns |
|
| % | 74 | 25 | 19 | 72 | 29 | 28 | ns |
|
| % | 65 | 30 | 19 | 73 | 29 | 28 | ns |
|
| % | 58 | 17 | 19 | 53 | 29 | 28 | ns |
COC: cumulus oocyte complex; Relative E2: E2/COC retrieved; Ovarian Response: (COC retrieved/Gonadotrophine dose) x 100; Oocyte Maturity: proportion of MII/COC retrieved; 2PN: proportion of 2PN/intact oocytes after ICSI; ≥7cell day3 = proportion of embryos with at least 7 cells on day3/2PN; Low Fragmentation: proportion of embryos with <10% fragmentation on day3/2PN; Good Quality Embryos: proportion of embryos on day 3 with <10% fragmentation and at least 7 cells/2PN; a Serum values as measured on day of hCG; ns: P>0.05; SD = standard deviation.
Figure 2t-test of normalized gene expression values of non-pregnant versus live birth related cumulus cell samples.
The graphs represent the differences in gene expression between the cumulus cell samples associated to an oocyte that after in vitro fertilization treatment resulted in a live birth (n = 19) or not (n = 28). Normalization was done to the mean of B2M and UBC. Only P-values <0.0042 were considered significant after Bonferroni correction. The total range of expressions found is depicted by the boxes and whiskers respectively representing the two inner and the two outer quartiles with centrally the median.
P-value of addition for the different genes tested.
| Variable |
| Variable |
|
|
| 0.01 |
| 0.38 |
|
| 0.01 |
| 0.43 |
|
| 0.04 |
| 0.50 |
|
| 0.05 |
| 0.61 |
|
| 0.06 |
| 0.68 |
|
| 0.16 |
| 0.75 |
The P-value of addition is obtained when each gene is inserted as first variable in a pregnancy model. The genes are ordered with increasing P-value.
Schematic overview of the multivariable models for live birth prediction.
| Total # of patients | # of pregnant patients | GPX3 | GSTA3 | GSTA4 | PGR | EFNB2 | AGE | Rel E2 | # Days stim | P model | PPV (%) | NPV (%) | Accuracy (%) | AUC | |
| Model 1 (3 genes) | 47 | 19 | xa | x | xa | 0.0015 | 68 | 79 | 73 | 0.82 | |||||
| Model 1 bis (Model 1 + patient and cycle parameters) |
| ||||||||||||||
| Model 2 (unlimited # of genes) | 47 | 19 | xa | xa | xa | x | x | 0 | 78 | 83 | 81 | 0.93 | |||
| Model 3 (Model 2 + patient and cycle parameters) | 42* | 16 | xa | xa | xa | xa | xa | x | x | x | 0 | 93 | 93 | 93 | 0.95 |
Only genes and factors that were at least retained once are listed. In Model 1 a maximum of three genes were retained to finalize the model. In Model 2 an unlimited number of genes were allowed into the model, if they could improve the P-value of the model. To try to improve Model 1 and Model 2 patient and cycle characteristics from Table 3 were allowed into the model. Only Model 2 could be improved and resulted in Model 3. x: factor significantly improving the model; #: number; ‘unlimited’ refers to the fact that all 12 genes were allowed into the model if they could improve the model; stim: ovarian stimulation; PPV: positive predictive value; NPV: negative predictive value; AUC: Area under the curve; a: Final type-III P-value <0.01 in the model;* only 42 patients were included to build this model as E2 values on day of hCG were missing for 5 patients.
Mathematical models for pregnancy prediction.
| Model 1 (max 3 genes) = | −2.25846+0.79256× |
| Model 1bis (max 3 genes + parameters |
|
| Model 2 (unlimited # of genes) = | −1.02049+0.63484× |
| Model 3 (unlimited # of genes + parameters | −11.26732 + 1.3462× |
Full mathematical models used to predict pregnancy outcome using cumulus cell gene expression values and patient and cycle characteristics. #: number.
Figure 3Receiver operating characteristic (ROC) curve of the 3 pregnancy models.
Multivariable models were built to predict the chance to pregnancy including the gene expression levels measured in cumulus cell samples associated to an oocyte that after in vitro fertilization treatment resulted in a live birth or not. For Model 3 patient and cycle characteristics were also included (from Table 3). Model 1 was limited to 3 genes and is composed of EFNB2, PGR and GSTA4. In Model 2 all genes were allowed into the model as long as they could improve the model. Five genes were retained for Model 2: EFNB2, PGR, GSTA4, GSTA3, GPX3. To try to improve Model 2, in Model 3 patient and cycle characteristics were allowed into the model if they could improve the P-value of the model: EFNB2, PGR, GSTA4, GSTA3, GPX3, age, Relative E2, and number of days of ovarian stimulation. The respective areas under the curve are 0.82, 0.93 and 0.95. Relative E2: E2 value measured on day of hCG over the number of cumulus oophorus complexes.
Comparison of gene expression levels of fresh cycles not resulting in pregnancy to frozen transfer cycles resulting in pregnancy (intra-patient analysis).
| Single gene analysis | Multivariable | |||||||||||
| Model 1 | Model 2 | |||||||||||
| Fresh/FRET | Outcome |
|
|
|
|
|
|
| Ranking | Ranking | ||
| Patient 1 | Fresh | not pregnant | ratio | 3.4 | 3.5 | 1.8 | 2.1 | 1.4 | 5.4 | 0.7 | 2 | 2 |
| FRET | clinical pregnancy | 1 | 1 | |||||||||
| Patient 2 | Fresh | not pregnant | ratio | 4.9 | 4.9 | 2.3 | 4.0 | 2.6 | 0.0 | 2.9 | 2 | 2 |
| FRET | clinical pregnancy | 1 | 1 | |||||||||
| Patient 3 | Fresh | not pregnant | ratio | 1.8 | 1.8 | 1.6 | 1.8 | 1.4 | 0.0 | 0.6 | 2 | 2 |
| FRET | clinical pregnancy | 1 | 1 | |||||||||
| Patient 4 | Fresh | not pregnant | ratio | 1.6 | 1.8 | 1.4 | 3.6 | 0.7 a | 1.1 | 1.0 | 1 b | 1 b |
| FRET | clinical pregnancy | 2 b | 2 b | |||||||||
| Patient 5 | Fresh | not pregnant | ratio | 4.1 | 3.2 | 4.1 | 1.5 | 1.2 | 1.2 | 1.0 | 2 | 2 |
| FRET | Live birth | 1 | 1 | |||||||||
| Patient 6 | Fresh | not pregnant | ratio | 1.4 | 1.3 | 1.3 | 1.0 a | 1.3 | 1.2 | 0.8 | 3 | 3 |
| FRET | not pregnant | ratio | 1.0 a | 0.6 a | 0.6 a | 0.7 a | 0.9 a | 0.8 | 0.6 | 2 | 2 | |
| FRET | clinical pregnancy | 1 | 1 | |||||||||
| Patient 7 | Fresh | not pregnant | ratio | 2.3 | 2.8 | 2.9 | 2.8 | 3.1 | 1.6 | 1.3 | 2 | 2 |
| FRET | Live birth | 1 | 1 | |||||||||
| Based on the paired t-test expected higher in: | pregnant | pregnant | pregnant | pregnant | pregnant | nlr | nlr | |||||
| Average: | 2.5 | 2.5 | 2.0 | 2.0 | 1.6 | 1.6 | 1.1 | |||||
| Min: | 1.0 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.6 | |||||
| Max: | 4.9 | 4.9 | 4.1 | 4.1 | 3.1 | 3.1 | 2.9 | |||||
| % corrected predictions based on expression level: | 86 | 86 | 86 | 86 | 71 | na | na | 86% | 86% | |||
|
| 0.006 | 0.026 | 0.037 | 0.033 | 0.074 | ns | ns | |||||
This Table gives an overview of the intra-patient analysis. Each line represents one cumulus complex. Per patient 2 or 3 cumulus complexes from 1 retrieval cycle were analyzed. Ratios of gene expression levels are always pregnant over non-pregnant. For patient 6, the cumulus complex of the pregnant FRET cycle was compared to the cumulus complexes of the fresh and the FRET non-pregnant cycle. Model 1 and 2 are respectively the models built up with 3 and 5 genes from Table 5. Ranking was obtained by inserting the expression values in the mathematical models from Table 6. Rank number ‘1’ is the oocyte with the highest chance to achieve pregnancy. ns: not significant; na: not applicable; nlr: no linear relation. a: the expression value is not higher or lower between pregnant and non-pregnant as expected based on the earlier results. b: the ranking is not correct using the multivariable models. FRET: frozen embryo transfer cycle.